Copyright
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Nov 16, 2021; 9(32): 9857-9868
Published online Nov 16, 2021. doi: 10.12998/wjcc.v9.i32.9857
Published online Nov 16, 2021. doi: 10.12998/wjcc.v9.i32.9857
Presepsin as a biomarker for risk stratification for acute cholangitis in emergency department: A single-center study
Han-Yu Zhang, Zhao-Qing Lu, Guo-Xing Wang, Miao-Rong Xie, Chun-Sheng Li, Department of Emergency Medicine, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China
Author contributions: Zhang HY, Xie MR, and Li CS designed the study; Zhang HY and Lu ZQ collected the samples and clinical data; Zhang HY measured presepsin, analyzed all the data, and performed the statistical analysis; Wang GX conducted clinical supervision.
Supported by National Natural Science Foundation of China , No. 81773931 ; and Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support “Yanfan” Project , No. ZYLX201802 .
Institutional review board statement: The study was reviewed and approved by the Beijing Friendship Hospital Institutional Review Board (Approval No. 2018-P2-063-01).
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: There are no conflicts of interest to report.
Data sharing statement: No additional data are available.
STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Chun-Sheng Li, PhD, Professor, Department of Emergency Medicine, Beijing Friendship Hospital, Capital Medical University, No. 95 Yong-an Road, Xicheng District, Beijing 100050, China. lcscyyy@163.com
Received: June 22, 2021
Peer-review started: June 22, 2021
First decision: July 26, 2021
Revised: July 28, 2021
Accepted: August 27, 2021
Article in press: August 27, 2021
Published online: November 16, 2021
Peer-review started: June 22, 2021
First decision: July 26, 2021
Revised: July 28, 2021
Accepted: August 27, 2021
Article in press: August 27, 2021
Published online: November 16, 2021
Core Tip
Core Tip: Although the mortality rate of acute cholangitis has decreased notably due to early drainage and antibiotic use, it remains higher in severe cholangitis. Early identification of severe cholangitis can reduce the mortality of patients with severe cholangitis. Presepsin is a promising biomarker for the early diagnosis and prognosis of bacterial infections. In this study, presepsin was found to be superior to white blood cell count, C-reactive protein, procalcitonin, and total bilirubin in predicting positive blood culture and assessing risk in patients with acute cholangitis in the emergency department.